Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

August 15, 2022

1 minute read

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

International Energy Agency To Draw Up Plan To Cut Oil Usage As Prices Surge: Reuters

Today, 6:22 AM

The International Energy Agency (IEA) head says they could plan to release more oil from stocks to ease surging…

Today, 6:22 AM

Evercore ISI Group analyst David Motemaden downgrades Allstate (NYSE:ALL) from Outperform to In-Line and lowers the price target from $142 to $135.

Today, 6:22 AM

Rubius Therapeutics Inc (NASDAQ: RUBY) has

Today, 6:22 AM

Atlantic Equities analyst Simon Clinch downgrades Moody's (NYSE:MCO) from Overweight to Neutral.